Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy (HYPOCAAVI)
Primary Purpose
Thyroid Diseases
Status
Recruiting
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
ICG
Control group
Sponsored by
About this trial
This is an interventional prevention trial for Thyroid Diseases focused on measuring Hypocalcemia, Hypoparathyroidism, Angiography
Eligibility Criteria
Inclusion Criteria:
- Patient having to undergo a total thyroidectomy
- Signed consent
- Patient beneficiary of a social security regimen
Exclusion Criteria:
- Minor patient under 18 years old
- Major patient protected by law or unable to give informed consent
- Pregnant or breastfeeding woman
- Thyroidectomy totalization
- History of thyroid or parathyroid surgery
- Participation refusal
- Known allergy to ICG
- Woman of child-bearing age not using adequate method of contraception
Sites / Locations
- CHRU de BrestRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
ICG group
Control group
Arm Description
Patient receiving 2 or 3 intraoperative injections of indocyanine green.
Patient benefiting from the traditional surgical act
Outcomes
Primary Outcome Measures
Compare the frequency of albumin-corrected hypocalcemia (blood sugar below 2 mmol/L, a sign associated with hypoparathyroidism) postoperatively between the ICG group and the control group.
Frequency of albumin-corrected hypocalcemia (≤2 mmol/L) within 48 hours postoperatively.
Secondary Outcome Measures
Evaluate the contribution of ICG angiography in the modification of the rate of definitive hypoparathyroidism after total thyroidectomy.
Occurrence (yes/no) of albumin-corrected (<2mmol/L) postoperative hypocalcemia at D8, M1 and M6
Determine the contribution of indocyanine green angiography (ICG) during the total thyroidectomy procedure for in vivo detection and preservation of parathyroid glands.
Modification (yes/no) of the surgical procedure by improving the detection of parathyroids or their vascularization during thyroidectomy with the use of indocyanine green angiography.
To evaluate the contribution of indocyanine green angiography in the prediction of postoperative hypocalcemia.
Intraoperative parathyroid vitality score (0=devascularized parathyroid gland to 2 = vascularized thyroid gland) when using indocyanine green angiography.
To determine the interest of indocyanine green angiography (ICG) in the prediction of hypoparathyroidism after total thyroidectomy.
Occurrence (yes/no) of hypo parathormone at D1 and D2 postoperatively (<10ng/L).
Compare the frequency of postoperative hypocalcemia, according to its grade (mild, moderate and deep), between the ICG group and the control group.
Frequency of mild (asymptomatic and >1.7mmol/l), moderate (symptomatic and >1.7mmol/l) and profound (<1.7mmol/l) hypocalcemia within 48 hours postoperatively.
Evaluate the tolerance of indocyanine green.
Occurrence of an adverse event related to the injection of indocyanine green.
Full Information
NCT ID
NCT04785443
First Posted
February 25, 2021
Last Updated
October 23, 2023
Sponsor
University Hospital, Brest
1. Study Identification
Unique Protocol Identification Number
NCT04785443
Brief Title
Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy
Acronym
HYPOCAAVI
Official Title
Contribution of Indocyanine Green Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 22, 2021 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
March 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Brest
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Hypoparathyroidism is the most common complication after a total thyroidectomy surgery. It becomes permanent after 6 months.
Untreated permanent hypoparathyroidism is a source of numerous complications in general and therefore requires lifelong replacement therapy resulting in a significant deterioration in quality of life.
The intraoperative use of indocyanine green (ICG) angiography has recently been described as a reliable means of detecting parathyroidism and predicting the risk of postoperative hypoparathyroidism.
This use could prove to be a way to preserve parathyroid in vivo and thus reduce post-operative hypoparathyroidism rates.
Detailed Description
Hypoparathyroidism is the most common complication after a total thyroidectomy surgery. It is most often transient but can sometimes be permanent when it persists for more than 6 months after surgery. The rates are variable, of the order of 32% for transient hypoparathyroidism and 1% for definitive hypoparathyroidism. Untreated permanent hypoparathyroidism is the source of many complications in general and therefore requires lifelong replacement therapy. The result is a significant deterioration in quality of life.
The mechanisms responsible for hypoparathyroidism during thyroidectomy are direct damage to the parathyroid glands, involuntary excision of these glands, and devascularization of these glands.
The detection of parathyroid glands and the prevention of hypoparathyroidism after thyroidectomy therefore represents a major challenge.
The intraoperative use of indocyanine green angiography has recently been described as a reliable means of detecting parathyroid and predicting the risk of postoperative hypoparathyroidism.
In addition, prior studies and intraoperative observations suggest that indocyanine green angiography during thyroid surgery may be a means of preserving parathyroid in vivo and thus reducing post-operative hypoparathyroidism rates.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thyroid Diseases
Keywords
Hypocalcemia, Hypoparathyroidism, Angiography
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Monocentric, comparative, randomized, single-blind, controlled trial against the reference method
Masking
Participant
Masking Description
Simple blind (only participant)
Allocation
Randomized
Enrollment
242 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
ICG group
Arm Type
Experimental
Arm Description
Patient receiving 2 or 3 intraoperative injections of indocyanine green.
Arm Title
Control group
Arm Type
Other
Arm Description
Patient benefiting from the traditional surgical act
Intervention Type
Drug
Intervention Name(s)
ICG
Intervention Description
During thyroidectomy surgery, the patient will received 2 or 3 injections of 5 mg as a bolus. The first one during the dissection of the first lobe, then during the dissection of the second lobe and finally if needed, a 3rd injection will be done at the end of the dissection.
Patients will then be followed during 6 months.
Intervention Type
Procedure
Intervention Name(s)
Control group
Intervention Description
During thyroidectomy surgery, patients are treated according to traditional surgery with detection of parathyroids with the naked eyes.
Patients will then be followed during 6 months.
Primary Outcome Measure Information:
Title
Compare the frequency of albumin-corrected hypocalcemia (blood sugar below 2 mmol/L, a sign associated with hypoparathyroidism) postoperatively between the ICG group and the control group.
Description
Frequency of albumin-corrected hypocalcemia (≤2 mmol/L) within 48 hours postoperatively.
Time Frame
Day 2
Secondary Outcome Measure Information:
Title
Evaluate the contribution of ICG angiography in the modification of the rate of definitive hypoparathyroidism after total thyroidectomy.
Description
Occurrence (yes/no) of albumin-corrected (<2mmol/L) postoperative hypocalcemia at D8, M1 and M6
Time Frame
Day 8, Month 1 and Month 6
Title
Determine the contribution of indocyanine green angiography (ICG) during the total thyroidectomy procedure for in vivo detection and preservation of parathyroid glands.
Description
Modification (yes/no) of the surgical procedure by improving the detection of parathyroids or their vascularization during thyroidectomy with the use of indocyanine green angiography.
Time Frame
Day 0
Title
To evaluate the contribution of indocyanine green angiography in the prediction of postoperative hypocalcemia.
Description
Intraoperative parathyroid vitality score (0=devascularized parathyroid gland to 2 = vascularized thyroid gland) when using indocyanine green angiography.
Time Frame
Day 0
Title
To determine the interest of indocyanine green angiography (ICG) in the prediction of hypoparathyroidism after total thyroidectomy.
Description
Occurrence (yes/no) of hypo parathormone at D1 and D2 postoperatively (<10ng/L).
Time Frame
Day 1 and Day 2
Title
Compare the frequency of postoperative hypocalcemia, according to its grade (mild, moderate and deep), between the ICG group and the control group.
Description
Frequency of mild (asymptomatic and >1.7mmol/l), moderate (symptomatic and >1.7mmol/l) and profound (<1.7mmol/l) hypocalcemia within 48 hours postoperatively.
Time Frame
D1 and D2
Title
Evaluate the tolerance of indocyanine green.
Description
Occurrence of an adverse event related to the injection of indocyanine green.
Time Frame
Day 1, Day 2, Day 10
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient having to undergo a total thyroidectomy
Signed consent
Patient beneficiary of a social security regimen
Exclusion Criteria:
Minor patient under 18 years old
Major patient protected by law or unable to give informed consent
Pregnant or breastfeeding woman
Thyroidectomy totalization
History of thyroid or parathyroid surgery
Participation refusal
Known allergy to ICG
Woman of child-bearing age not using adequate method of contraception
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean-Christophe LECLERE, PhD
Phone
0298223630
Ext
+33
Email
jean-christophe.leclere@chu-brest.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Christophe LECLERE, PhD
Organizational Affiliation
CHRU de Brest
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHRU de Brest
City
Brest
ZIP/Postal Code
29609
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Christophe LECLERE
First Name & Middle Initial & Last Name & Degree
Gael POTARD
First Name & Middle Initial & Last Name & Degree
Julien PREVOT
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
All collected data that underlie results in a publication.
IPD Sharing Time Frame
Data will be available beginning three years and ending fifteen years following the final study report completion.
IPD Sharing Access Criteria
Data access request will be reviewed by the internal committee of Brest University Hospital. Requestor will be required to sign and complete a data access agreement.
Learn more about this trial
Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy
We'll reach out to this number within 24 hrs